Aussie heart test given the go-ahead
26 March, 2002 by Tanya HollisAn Australian-developed, non-invasive test to measure arterial stiffness and heart function has been given the official nod from the United States.
Nerve drug fails in Phase II
22 March, 2002 by Tanya HollisA drug intended to reduce peripheral nerve damage in cancer patient has failed in a clinical trial.
Queensland gets closer to Texas
20 March, 2002 by Pete YoungCloser ties between a Texas biomedical research powerhouse and Queensland biotech institutes have been foreshadowed by Queensland Premier Peter Beattie.
Bug DNA used to fight disease
20 March, 2002 by Pete YoungAustralian scientists are claiming a world-first technique for using DNA 'fingerprints' of bacteria as an early warning system against disease epidemics.
Polartechnics promises more accurate cervical screen
19 March, 2002 by Daniella GoldbergA cervical screening product that its developer claims is more accurate than the conventional pap smear in detecting earlier grades of pre-cancer will be on the European market within the next few months, and in Australia by the end of the year.
Biotron sacrifices profits for R&D
15 March, 2002 by Tanya HollisBiotechnology licensing company Biotron (ASX:BIT) has sacrificed profits in favour of ramping up research and development expenditure into its cancer diagnostic and anti-HIV drug programs.
Sirtex looks to Europe following FDA success
12 March, 2002 by Daniella GoldbergSmall particle technology company Sirtex Medical is seeking European approval for its liver cancer treatment, following last week's announcement it had been approved by the US Food and Drug Administration.
Epilepsy breakthrough for Adelaide researchers
11 March, 2002 by Melissa TrudingerA surprise finding by a team of Adelaide scientists has provided the first evidence that the same gene on the X-chromosome may be responsible for some forms of both epilepsy and intellectual disability.
FDA approves Sirtex cancer treatment
08 March, 2002 by Iain ScottSydney company Sirtex Medical's novel liver cancer treatment has been approved by the US Food and Drug Administration (FDA), opening the door to what the company says is a billion dollar market.
Diabetes project sets new trend for NHMRC
06 March, 2002 by Daniella GoldbergThe National Health and Medical Research Council (NHMRC) has come up with a new model for commercialising medical research.
Tumour barcode spells hope for better cancer diagnosis
19 February, 2002 by Tanya HollisCancer patients could face improved diagnoses and survival rates with the development of a tumour barcode.
Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
